Sight Sciences Inc (SGHT)

$7.70 +0.23 (3.08%)
Market Cap 406.44M
Revenue (ttm) 77.36M
Net Income (ttm) -38.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -49.68%
Debt to Equity Ratio 0.75
Volume 297,600
Avg Vol 206,938
Day's Range N/A - N/A
Shares Out 54.41M
Stochastic %K 92%
Beta 2.38
Analysts Strong Sell
Price Target $8.60

Company Profile

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure...

Industry: Medical Devices
Sector: Healthcare
Phone: 877 266 1144
Fax: 650 352 4401
Address:
4040 Campbell Avenue, Suite 100, Menlo Park, United States
prismmarketview
prismmarketview Aug. 6 at 4:08 PM
PRISM Mid-Day Movers: Beauty & Wellness and MedTech are Today’s Leaders. The Honest Company, Inc. (NASDAQ: $HNST )is ripping higher today, with the stock up about 40% as shares rocket to a new 52‑week high near 5.84. Sight Sciences, Inc. (NASDAQ: $SGHT ) is surging today, with the stock up roughly 27% intraday as buyers pile in following a strong second‑quarter report. Other Notable Movers: Magnite ( $MGNI )up 19% Cadre Holdings ( $CDRE ) up 17% Nuburu ( $BURU ) down -39% https://prismmarketview.com/prism-mid-day-movers-beauty-wellness-and-medtech-are-todays-leaders/
0 · Reply
cnichter118
cnichter118 Aug. 6 at 12:40 PM
$APP jump on $SGHT riiight now!
1 · Reply
cnichter118
cnichter118 Aug. 5 at 11:17 PM
$RDW $SGHT
0 · Reply
cnichter118
cnichter118 Aug. 5 at 11:16 PM
$CLRO $SGHT
0 · Reply
EarningsInsider
EarningsInsider Aug. 5 at 9:45 PM
https://www.marketbeat.com/earnings/reports/2026-8-5-sight-sciences-inc-stock/ $SGHT Sight Sciences Earnings Transcript
0 · Reply
cnichter118
cnichter118 Aug. 5 at 8:59 PM
$SGHT
1 · Reply
topstockalerts
topstockalerts Aug. 5 at 8:43 PM
$SGHT the trend has a very natural feel to it.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 5 at 8:15 PM
$SGHT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.08 up 65.22% YoY • Reported revenue of $23.39M up 19.55% YoY • Sight Sciences raised its full-year 2026 revenue guidance to a range of $88 million to $92 million and reduced its adjusted operating expenses guidance to $92 million to $94 million.
0 · Reply
BuyLongHoldStrong
BuyLongHoldStrong Aug. 5 at 7:05 PM
$DBGI $VRRM $SGHT In all three 🍀
0 · Reply
Johnnytwofour2
Johnnytwofour2 Aug. 5 at 1:53 PM
$SGHT Not much here but tears and broken dreams at this point.
0 · Reply
Latest News on SGHT
Sight Sciences price target raised to $8 from $7 at UBS

2026-08-06T12:49:54.000Z - 4 days ago

Sight Sciences price target raised to $8 from $7 at UBS

Sight Sciences reports Q2 EPS (8c), consensus (14c)

2026-08-05T21:26:24.000Z - 5 days ago

Sight Sciences reports Q2 EPS (8c), consensus (14c)

Sight Sciences raises FY26 revenue view to $88M-$92M from $83M-$89M

2026-08-05T21:26:05.000Z - 5 days ago

Sight Sciences raises FY26 revenue view to $88M-$92M from $83M-$89M

Sight Sciences Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 days ago

Sight Sciences Earnings Call Transcript: Q2 2026

Sight Sciences Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 days ago

Sight Sciences Earnings release: Q2 2026

Sight Sciences Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 5 days ago

Sight Sciences Quarterly report: Q2 2026

Sight Sciences Reports Second Quarter 2026 Financial Results

Aug 5, 2026, 4:05 PM EDT - 5 days ago

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

Aug 5, 2026, 4:04 PM EDT - 5 days ago

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

Sight Sciences Slides: Investor presentation

Aug 5, 2026, 4:00 PM EDT - 5 days ago

Sight Sciences Slides: Investor presentation

Sight Sciences announces FDA clearance of Omni Ultra Surgical System

2026-08-04T21:40:19.000Z - 6 days ago

Sight Sciences announces FDA clearance of Omni Ultra Surgical System

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Aug 4, 2026, 5:37 PM EDT - 6 days ago

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Sight Sciences resumed with a Buy at UBS

2026-07-28T12:05:26.000Z - 13 days ago

Sight Sciences resumed with a Buy at UBS

Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Jul 22, 2026, 4:05 PM EDT - 19 days ago

Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Sight Sciences price target raised to $6 from $5.15 at Citi

2026-07-08T10:40:43.000Z - 4 weeks ago

Sight Sciences price target raised to $6 from $5.15 at Citi

Sight Sciences Transcript: AGM 2026

Jun 4, 2026, 12:00 PM EDT - 2 months ago

Sight Sciences Transcript: AGM 2026

Sight Sciences price target raised to $5.15 from $4.35 at Citi

2026-05-28T12:14:51.000Z - 2 months ago

Sight Sciences price target raised to $5.15 from $4.35 at Citi

Sight Sciences Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 26, 2026, 12:00 PM EDT - 2 months ago

Sight Sciences Transcript: Stifel 2026 Virtual Ophthalmology Forum

Sight Sciences Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 6:15 PM EDT - 3 months ago

Sight Sciences Transcript: Bank of America Global Healthcare Conference 2026

Sight Sciences reports Q1 EPS (24c), consensus (20c)

2026-05-07T00:48:24.000Z - 3 months ago

Sight Sciences reports Q1 EPS (24c), consensus (20c)

Sight Sciences raises FY26 revenue view to $83M-$89M from $82M-$88M

2026-05-07T00:47:54.000Z - 3 months ago

Sight Sciences raises FY26 revenue view to $83M-$89M from $82M-$88M

Sight Sciences Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sight Sciences Earnings Call Transcript: Q1 2026

Sight Sciences Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sight Sciences Earnings release: Q1 2026

Sight Sciences Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Sight Sciences Quarterly report: Q1 2026

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

May 6, 2026, 4:05 PM EDT - 3 months ago

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

Sight Sciences Slides: Investor presentation

May 6, 2026, 4:00 PM EDT - 3 months ago

Sight Sciences Slides: Investor presentation

Sight Sciences to Present at Two Upcoming Investor Conferences

Apr 29, 2026, 4:05 PM EDT - 3 months ago

Sight Sciences to Present at Two Upcoming Investor Conferences

Sight Sciences Announces the Release of its Sustainability Report

Apr 22, 2026, 4:45 PM EDT - 3 months ago

Sight Sciences Announces the Release of its Sustainability Report

Sight Sciences Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

Sight Sciences Proxy statement: Proxy filing

Sight Sciences Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

Sight Sciences Proxy statement: Proxy filing

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

Apr 21, 2026, 4:05 PM EDT - 3 months ago

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

Sight Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 13, 2026, 2:15 PM EDT - 4 months ago

Sight Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference

Sight Sciences price target lowered to $4.35 from $5 at Citi

2026-04-07T10:56:28.000Z - 4 months ago

Sight Sciences price target lowered to $4.35 from $5 at Citi

Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 1, 2026, 4:05 PM EDT - 4 months ago

Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

Mar 30, 2026, 4:05 PM EDT - 4 months ago

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

Sight Sciences awarded monetary damages by district court against Alcon

2026-03-30T11:30:29.000Z - 4 months ago

Sight Sciences awarded monetary damages by district court against Alcon

ALC

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

Mar 30, 2026, 7:05 AM EDT - 4 months ago

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

Sight Sciences price target lowered to $5 from $6.50 at Citi

2026-03-11T09:25:10.000Z - 5 months ago

Sight Sciences price target lowered to $5 from $6.50 at Citi

Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 6, 2026, 2:13 PM EST - 5 months ago

Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Sight Sciences price target lowered to $6.50 from $9.10 at Citi

2026-03-06T11:37:05.000Z - 5 months ago

Sight Sciences price target lowered to $6.50 from $9.10 at Citi

Sight Sciences price target lowered to $11 from $12 at UBS

2026-03-06T11:21:23.000Z - 5 months ago

Sight Sciences price target lowered to $11 from $12 at UBS

Sight Sciences Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

Sight Sciences Earnings Call Transcript: Q4 2025

Sight Sciences Annual report: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

Sight Sciences Annual report: Q4 2025

Sight Sciences Earnings release: Q4 2025

Mar 4, 2026, 4:30 PM EST - 5 months ago

Sight Sciences Earnings release: Q4 2025

Sight Sciences reports Q4 EPS (8c), consensus (14c)

2026-03-04T21:27:54.000Z - 5 months ago

Sight Sciences reports Q4 EPS (8c), consensus (14c)

Sight Sciences sees FY26 revenue $82M-$88M, consensus $86.11M

2026-03-04T21:26:13.000Z - 5 months ago

Sight Sciences sees FY26 revenue $82M-$88M, consensus $86.11M

Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

Mar 4, 2026, 4:05 PM EST - 5 months ago

Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

Sight Sciences Slides: investor presentation

Mar 4, 2026, 4:00 PM EST - 5 months ago

Sight Sciences Slides: investor presentation

Sight Sciences price target raised to $8 from $6 at Stifel

2026-03-02T13:01:30.000Z - 5 months ago

Sight Sciences price target raised to $8 from $6 at Stifel

Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Feb 18, 2026, 4:05 PM EST - 6 months ago

Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

Sight Sciences resumed with an Outperform at William Blair

2026-01-30T12:21:13.000Z - 6 months ago

Sight Sciences resumed with an Outperform at William Blair

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

Jan 13, 2026, 7:05 AM EST - 7 months ago

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

Sight Sciences Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 11:20 AM EST - 9 months ago

Sight Sciences Transcript: Stifel 2025 Healthcare Conference

Sight Sciences Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Sight Sciences Earnings Call Transcript: Q3 2025

Sight Sciences Quarterly report: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Sight Sciences Quarterly report: Q3 2025

Sight Sciences Earnings release: Q3 2025

Nov 6, 2025, 4:30 PM EST - 9 months ago

Sight Sciences Earnings release: Q3 2025

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Nov 6, 2025, 4:05 PM EST - 9 months ago

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

Nov 6, 2025, 4:04 PM EST - 9 months ago

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

Sight Sciences Slides: Investor Presentation

Nov 5, 2025, 6:00 PM EST - 9 months ago

Sight Sciences Slides: Investor Presentation

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 23, 2025, 4:05 PM EDT - 10 months ago

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

Oct 17, 2025, 7:00 AM EDT - 10 months ago

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

Sep 17, 2025, 7:00 AM EDT - 11 months ago

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

Sight Sciences Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 1:50 PM EDT - 11 months ago

Sight Sciences Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

Sep 9, 2025, 7:05 AM EDT - 11 months ago

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

Sep 2, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Aug 26, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Sight Sciences Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Sight Sciences Earnings Call Transcript: Q2 2025

Sight Sciences Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Sight Sciences Quarterly report: Q2 2025

Sight Sciences Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Sight Sciences Earnings release: Q2 2025

Sight Sciences Slides: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Sight Sciences Slides: Q2 2025

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

Jul 30, 2025, 7:00 AM EDT - 1 year ago

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

Sight Sciences Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 27, 2025, 12:00 PM EDT - 1 year ago

Sight Sciences Transcript: Stifel 2025 Virtual Ophthalmology Forum

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

May 14, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

Sight Sciences Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Sight Sciences Earnings Call Transcript: Q1 2025

Sight Sciences Quarterly report: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Sight Sciences Quarterly report: Q1 2025

Sight Sciences Earnings release: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Sight Sciences Earnings release: Q1 2025

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

May 8, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

Sight Sciences Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Sight Sciences Proxy statement: Proxy Filing

Sight Sciences Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Sight Sciences Proxy statement: Proxy Filing

Sight Sciences Appoints Gary Burbach to its Board of Directors

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences Appoints Gary Burbach to its Board of Directors

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

Apr 21, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

Sight Sciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 8, 2025, 3:45 PM EDT - 1 year ago

Sight Sciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Mar 25, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Sight Sciences Earnings Call Transcript: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Sight Sciences Earnings Call Transcript: Q4 2024

Sight Sciences Annual report: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Sight Sciences Annual report: Q4 2024

Sight Sciences Earnings release: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Sight Sciences Earnings release: Q4 2024

Sight Sciences Slides: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Sight Sciences Slides: Q4 2024

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

Mar 5, 2025, 4:05 PM EST - 1 year ago

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

Sight Sciences Transcript: Citi’s 2025 Medtech and Life Sciences Access Day

Feb 27, 2025, 10:15 AM EST - 1 year ago

Sight Sciences Transcript: Citi’s 2025 Medtech and Life Sciences Access Day

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

Feb 24, 2025, 4:05 PM EST - 1 year ago

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

Feb 19, 2025, 4:05 PM EST - 1 year ago

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day

Feb 13, 2025, 4:05 PM EST - 1 year ago

Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

Dec 19, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

Sight Sciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 3:30 PM EST - 1 year ago

Sight Sciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:05 PM EST - 1 year ago

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Sight Sciences Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Sight Sciences Earnings Call Transcript: Q3 2024

Sight Sciences Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Sight Sciences Quarterly report: Q3 2024

Sight Sciences Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Sight Sciences Earnings release: Q3 2024

Sight Sciences Slides: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Sight Sciences Slides: Q3 2024

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

Oct 17, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

Sight Sciences Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 4, 2024, 4:50 PM EDT - 2 years ago

Sight Sciences Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sight Sciences Earnings Call Transcript: Q2 2024

Aug 1, 2024, 4:30 PM EDT - 2 years ago

Sight Sciences Earnings Call Transcript: Q2 2024

Sight Sciences Quarterly report: Q2 2024

Aug 1, 2024, 4:30 PM EDT - 2 years ago

Sight Sciences Quarterly report: Q2 2024

Sight Sciences Earnings release: Q2 2024

Aug 1, 2024, 4:30 PM EDT - 2 years ago

Sight Sciences Earnings release: Q2 2024

Sight Sciences Slides: Q2 2024

Aug 1, 2024, 4:30 PM EDT - 2 years ago

Sight Sciences Slides: Q2 2024

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

Jul 18, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

Sight Sciences Announces the Release of its First Sustainability Report

Jun 10, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Release of its First Sustainability Report

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

May 28, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

May 28, 2024, 8:30 AM EDT - 2 years ago

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

Sight Sciences Transcript: BofA Securities 2024 Health Care Conference

May 14, 2024, 11:15 AM EDT - 2 years ago

Sight Sciences Transcript: BofA Securities 2024 Health Care Conference

Sight Sciences Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Sight Sciences Earnings Call Transcript: Q1 2024

Sight Sciences Quarterly report: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Sight Sciences Quarterly report: Q1 2024

Sight Sciences Earnings release: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Sight Sciences Earnings release: Q1 2024

Sight Sciences Slides: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Sight Sciences Slides: Q1 2024

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

May 2, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

Apr 29, 2024, 8:05 AM EDT - 2 years ago

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

Sight Sciences Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Sight Sciences Proxy statement: Proxy Filing

Sight Sciences Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Sight Sciences Proxy statement: Proxy Filing

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

Apr 18, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2

Apr 10, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2

Sight Sciences Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 9, 2024, 3:45 PM EDT - 2 years ago

Sight Sciences Transcript: 23rd Annual Needham Virtual Healthcare Conference

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Apr 2, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

prismmarketview
prismmarketview Aug. 6 at 4:08 PM
PRISM Mid-Day Movers: Beauty & Wellness and MedTech are Today’s Leaders. The Honest Company, Inc. (NASDAQ: $HNST )is ripping higher today, with the stock up about 40% as shares rocket to a new 52‑week high near 5.84. Sight Sciences, Inc. (NASDAQ: $SGHT ) is surging today, with the stock up roughly 27% intraday as buyers pile in following a strong second‑quarter report. Other Notable Movers: Magnite ( $MGNI )up 19% Cadre Holdings ( $CDRE ) up 17% Nuburu ( $BURU ) down -39% https://prismmarketview.com/prism-mid-day-movers-beauty-wellness-and-medtech-are-todays-leaders/
0 · Reply
cnichter118
cnichter118 Aug. 6 at 12:40 PM
$APP jump on $SGHT riiight now!
1 · Reply
cnichter118
cnichter118 Aug. 5 at 11:17 PM
$RDW $SGHT
0 · Reply
cnichter118
cnichter118 Aug. 5 at 11:16 PM
$CLRO $SGHT
0 · Reply
EarningsInsider
EarningsInsider Aug. 5 at 9:45 PM
https://www.marketbeat.com/earnings/reports/2026-8-5-sight-sciences-inc-stock/ $SGHT Sight Sciences Earnings Transcript
0 · Reply
cnichter118
cnichter118 Aug. 5 at 8:59 PM
$SGHT
1 · Reply
topstockalerts
topstockalerts Aug. 5 at 8:43 PM
$SGHT the trend has a very natural feel to it.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 5 at 8:15 PM
$SGHT Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.08 up 65.22% YoY • Reported revenue of $23.39M up 19.55% YoY • Sight Sciences raised its full-year 2026 revenue guidance to a range of $88 million to $92 million and reduced its adjusted operating expenses guidance to $92 million to $94 million.
0 · Reply
BuyLongHoldStrong
BuyLongHoldStrong Aug. 5 at 7:05 PM
$DBGI $VRRM $SGHT In all three 🍀
0 · Reply
Johnnytwofour2
Johnnytwofour2 Aug. 5 at 1:53 PM
$SGHT Not much here but tears and broken dreams at this point.
0 · Reply
mimiwor
mimiwor Aug. 5 at 11:53 AM
$SGHT so black rock bought this above $7 this year huh
0 · Reply
ExploringTrades
ExploringTrades Aug. 5 at 10:42 AM
Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $SGHT $CRCL $RITR %%
0 · Reply
Roronao
Roronao Aug. 5 at 10:06 AM
$SGHT $KODK Si
0 · Reply
notreload_ai
notreload_ai Aug. 5 at 8:44 AM
$SGHT gets FDA clearance for OMNI Ultra, the first single-pass implant-free MIGS device for glaucoma. https://notreload.xyz/xy/sght-stock-jumps-on-fda-omni-ultra-clearance/
0 · Reply
BuyLongHoldStrong
BuyLongHoldStrong Aug. 5 at 8:39 AM
$SGHT FDA Approved. What’s their cash run away?
1 · Reply
DonCorleone77
DonCorleone77 Aug. 5 at 3:38 AM
$WYNN $PCTY $SGHT $TDC $VSAT AFTER-HOURS MOVERS: Currently Higher After Earnings: - Digital Turbine (APPS) up 30.6% - Travere Therapeutics (TVTX) up 13.9% - Arista Networks (ANET) up 11.1% - Ultragenyx (RARE) up 6.4% - Booking (BKNG) up 5.6% - Wynn Resorts (WYNN) up 4.7% - Paylocity (PCTY) up 3.3% Currently Also Higher: - Sight Sciences (SGHT) up 11.4% after receiving FDA 510(k) clearance of the Omni Ultra Surgical System Currently Lower After Earnings: - Teradata (TDC) down 16.0% - Atomera (ATOM) down 10.9% - ViaSat (VSAT) down 8.9% - Chemours (CC) down 7.4% - Match Group (MTCH) down 9.8% - Pinterest (PINS) down 8.6% - AMD (AMD) down 8.8% - Lucid Group (LCID) down 7.9% - DaVita (DVA) down 6.6% - SpaceX (SPCX) down 7.5% - Lattice Semiconductor (LSCC) down 4.5% - Coupang (CPNG) down 7.3%.
0 · Reply
mimiwor
mimiwor Aug. 5 at 1:45 AM
$SGHT https://finviz.com/news/377237/sight-sciences-receives-fda-510k-clearance-of-the-omni-ultra-surgical-system
0 · Reply
focafoca99
focafoca99 Aug. 4 at 11:44 PM
$SGHT cleared its OMNI Ultra system with FDA 510(k) clearance for glaucoma surgery.
0 · Reply
mimiwor
mimiwor Aug. 4 at 11:30 PM
$SGHT
0 · Reply
mimiwor
mimiwor Aug. 4 at 11:18 PM
$SGHT their expected ER was great...this price action was manipulated by option trader;; well this unexpected positive news may screwed them up
0 · Reply
vvvvvvrebel89130
vvvvvvrebel89130 Aug. 4 at 11:18 PM
$SGHT volume, could run
0 · Reply
topstockalerts
topstockalerts Aug. 4 at 11:18 PM
$SGHT buyers seem to be in no rush to let this go.
0 · Reply